Compare Cardinal Health Inc (CAH) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs PepsiCo, Inc. — how do they compare? Cardinal Health Inc trades at $236.94 (market cap $55.88B), while PepsiCo, Inc. trades at $137.51 (market cap $188.91B). The key difference: PepsiCo, Inc. is far larger — about 3.4× Cardinal Health Inc's market cap, and PepsiCo, Inc. pays the higher dividend (4.28%). Which is the better fit depends on your goals.
| CAH | PEP | |
|---|---|---|
Market Cap | $55.88B | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $240.26 | $170.44 |
52-Week Low | $146.04 | $134.95 |
Enterprise Value | $59.91B | $231.41B |
Dividend Yield | 0.86% | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.
Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.
PepsiCo (PEP) trades at $137.69, down 0.95% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company maintains strong fundamentals with $93.93B revenue in 2025, 10.78% net margin, and consistent dividend payments. Recent news highlights price adjustments for snack products and sponsorship withdrawals, while analysts project 15% upside to the $158.79 consensus target.
PepsiCo presents a mixed outlook with solid fundamentals and dividend yield offset by near-term price pressure and competitive challenges. The stock offers value at current levels for income investors, though execution risks in North America and consumer pricing sensitivity require monitoring. Wall Street maintains cautious optimism with 64% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
